iRhythm Technologies (NASDAQ:IRTC) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement.

Analysts anticipate iRhythm Technologies to report an earnings per share (EPS) of $-0.58.

The market awaits iRhythm Technologies's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.

It's important for new investors to understand that guidance can be a significant driver of stock prices.

Historical Earnings Performance

Last quarter the company beat EPS by $0.28, which was followed by a 12.28% drop in the share price the next day.

Here's a look at iRhythm Technologies's past performance and the resulting price change:

Performance of iRhythm Technologies Shares

Shares of iRhythm Technologies were trading at $76.3 as of October 28. Over the last 52-week period, shares are down 1.27%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.

Analyst Views on iRhythm Technologies

For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding iRhythm Technologies.

The consensus rating for iRhythm Technologies is Buy, derived from 10 analyst ratings. An average one-year price target of $109.1 implies a potential 42.99% upside.

Comparing Ratings with Peers

The analysis below examines the analyst ratings and average 1-year price targets of Inari Medical, Enovis and QuidelOrtho, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.

Comprehensive Peer Analysis Summary

Within the peer analysis summary, vital metrics for Inari Medical, Enovis and QuidelOrtho are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

Key Takeaway:

iRhythm Technologies ranks first in revenue growth among its peers. It has the lowest gross profit margin. The company has the lowest return on equity.

Delving into iRhythm Technologies's Background

A Deep Dive into iRhythm Technologies's Financials

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Net Margin: iRhythm Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -13.58% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): iRhythm Technologies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -21.22%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): iRhythm Technologies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.2%, the company may face hurdles in achieving optimal financial returns.

Debt Management: With a high debt-to-equity ratio of 7.43, iRhythm Technologies faces challenges in effectively managing its debt levels, indicating potential financial strain.

To track all earnings releases for iRhythm Technologies visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.